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http://www.molecularpain.com/content/8/1/40RESEARCH Open AccessEthyl pyruvate attenuates formalin-induced
inflammatory nociception by inhibiting neuronal
ERK phosphorylation
Min Jung Lee1,2, Minhee Jang1, Hyuk-Sang Jung1, Sung-Hoon Kim2 and Ik-Hyun Cho1*Abstract
Background: Ethyl pyruvate (EP) possesses anti-inflammatory activity. However, the potential anti-nociceptive value
of EP for the treatment of the inflammatory nociception is largely unknown. We investigated whether EP could have
any anti-nociceptive effect on inflammatory pain, after systemic administration of EP (10, 50, and 100 mg/kg, i.p.),
1 hour before formalin (5%, 50 μl) injection into the plantar surface of the hind paws of rats.
Results: EP significantly decreased formalin-induced nociceptive behavior during phase II, the magnitude of paw
edema, and the activation of c-Fos in L4-L5 spinal dorsal horn. EP also attenuated the phosphorylation of extracellular
signal-regulated kinase (ERK) in the neurons of L4-L5 spinal dorsal horn after formalin injection. Interestingly, the i.t.
administration of PD98059, an ERK upstream kinase (MEK) inhibitor, completely blocked the formalin-induced
inflammatory nociceptive responses.
Conclusions: These results demonstrate that EP may effectively inhibit formalin-induced inflammatory nociception via
the inhibition of neuronal ERK phosphorylation in the spinal dorsal horn, indicating its therapeutic potential in
suppressing acute inflammatory pain.
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Pyruvate (CH3COCOO
−), the anionic form of a simple
alpha-keto acid, plays a key role in intermediary metabol-
ism as a product of glycolysis and as the starting substrate
for the tricarboxylic acid (TCA) cycle [1,2]. Pyruvate is also
an important endogenous scavenger of hydrogen peroxide
(H2O2) and other reactive oxygen species (ROS), and an
anti-inflammatory agent [1-3]. However, its poor stability in
solution may limit its use as a therapeutic agent.
Ethyl pyruvate (EP), a stable and lipophilic derivative of
pyruvate, has therapeutic potential in improving survival
and/or ameliorating organ dysfunction in a wide variety of
preclinical models of critical illnesses, such as hemorrhagic
shock, severe sepsis, acute respiratory distress syndrome,
acute pancreatitis, and intestinal, renal, or hepatic injuries
in ischemic animal models [1-5]. Also, EP has neuroprotec-
tive effects against ischemic/traumatic brain injury [6-9],* Correspondence: ihcho@khu.ac.kr
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reproduction in any medium, provided the orParkinson’s disease [10,11], hypoxic-ischemic brain injury
[12], and spinal cord ischemic/traumatic injury [13,14].
EP has additionally been reported to exert an anti-
inflammatory effect in RAW 264.7 macrophage-like cells
and lipopolysaccharide (LPS)-induced BV2 microglial
cells by suppressing the activation of the nuclear factor-
kappa B (NF-κB), extracellular signal-regulated kinase
(ERK), and p38 mitogenactivated protein kinase (MAPK)
pathways [15,16]. Recently, we reported that EP attenu-
ates kainic acid-induced hippocampal neuronal death
through its anti-inflammatory effects [17], and that the
anti-inflammatory actions of EP include inhibiting ROS-
dependent STAT signaling in activated microglia [18].
These findings raise the possibility that EP may behave
as a potential effecter in other disease models.
Phosphorylation of ERK, a MAPK subfamily members,
occurs in spinal dorsal horn (DH) neurons in response to
injury and inflammation induced hyperalgesia of the per-
ipheral tissue [19-21], and in a murine model of visceral
pain [22,23]. Interestingly, phospho (p)-ERK is induced in
spinal DH neurons immediately after nerve injury (10 min. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cytes 3 weeks later [24]. This sequential induction of p-
ERK in different cell types at different times is important
for neuropathic pain development at different phases [24].
Intrathecal (i.t.) injection of specific inhibitor, which spe-
cifically attenuates ERK activity, reduces nociceptive re-
sponse behavior in inflammatory pain and CFA-induced
joint inflammation [25], and reduces visceral pain caused
by intracolonic capsacin [26]. These studies suggest an es-
sential role of ERK in the development and maintenance
of inflammatory or neuropathic hyperalgesia [19,20,27].
However, very little is known about the possible link, mo-
lecular signaling mechanisms, between p-ERK and EP
evoked by an acute inflammatory pain.
The present study addressed the role of EP on spinal
ERK in modulating acute inflammatory pain. The study
hypothesis was that EP attenuates formalin-induced in-
flammatory nociception by inhibiting the phosphoryl-
ation of the neuronal ERK in the spinal cord.
Results
EP inhibits phase II, but not phase I, formalin-induced
nociceptive response
Plantar injection of formalin produces an acute inflammatory
nociceptive response [28,29]. In present study, the number of
nociceptive responses were counted and totaled in 5 minute
intervals for 60 minutes following formalin administration
(5%, 50 μl). Saline-treated control rats displayed discrete bi-
phasic behavioral responses consisting of an early short-
lasting response (phase I, 0–10 minutes post-injection), fol-
lowed by a late, prolonged response (phase II, approximately
16–60 minutes post-injection). These two phases were sepa-
rated by a quiescent period (11–15 minutes post-injection)
(Figures 1A and 1B) [28,29]. The duration of licking, lifting,
and rubbing of the ipsilateral hind paw, which were consid-
ered to be nociceptive behaviors in the formalin model,
peaked around 36–40 minutes after formalin intraplantar in-
jection with maximal nociceptive behavior per minute of
32.6±3.4 seconds, which was followed by a gradually decline
(Figure 1A). The nociceptive behavior was compared be-
tween the saline- and EP [10, 50, and 100 mg/kg, intraperito-
neal (i.p.)]-administrated rats. Nociceptive behavior by
subcutaneous irritation during phase I was not different be-
tween the groups, but during phase II, was remarkably
inhibited in the EP-administrated rats in a dose-dependent
manner (Figure 1A). The total number of nociceptive
responses during phase II after formalin injection in the sa-
line pre-treatment group was 163.2±18.6 seconds/minute.
However, the total number of nociceptive responses was sig-
nificantly decreased by pre-treatment of EP in a dose-
dependent pattern (10 mg/kg, 117.0±14.5; 50 mg/kg,
96.4±11.2; 100 mg/kg, 74.0±8.3; Figure 1B). I.p. injection of
either saline or EP (100 mg/kg) alone, did not alter the be-
havior of the animals (data not shown). These results suggestthat EP has an anti-nociceptive effect on formalin-induced
inflammatory nociception.
EP reduces formalin-induced paw edema
Intraplantar injection of formalin elicits significant inflam-
mation (i.e. edema) in the center of the sole of the hind
paw [30]. Therefore, to confirm whether the apparent at-
tenuation of formalin-induced nociceptive behavior during
phase II following EP administration reflected the effect of
EP on the on-going peripheral inflammation produced by
formalin injection, the size changes of the hind paw edema
were compared between the saline- and EP-administrated
rats (control, n =15; 10 mg/kg, n=14; 50 mg/kg, n=10;
100 mg/kg, n=13). To investigate the change of edema size,
the foot thickness in the hind paw dorsal-plantar axis was
determined by measurements with a fine caliper. As shown
in Figure 1C, the thickness of the ipsilateral paw edema was
increased 177.1±6.3% compared to the thickness of the ip-
silateral paw before formalin injection. However, the thick-
ness of the paw edema in the formalin-evoked group was
significantly reduced by administration of EP in a dose-
dependent manner (151.4±3.1%~64.6±3.3%) (Figure 1C).
EP reduces formalin-induced c-fos expression in the
spinal cord
Because c-Fos, the protein product of the immediate-early
gene c-fos, is a neuroactive marker that can be used to
analyze nociceptive pathways [31-33], we compared the level
of spinal c-Fos expression between the saline- or formalin-
injected rats (n=8/group) 36–40 minutes after formalin in-
jection, the time at which the introduced formalin pro-
duced the maximal effects on nociceptive behavior
(Figure 1A). c-Fos-immunoreactive (IR) cells were evaluated
in the superficial laminae (I-II) and deep laminae (III-IV) of
the DH in L4-L5 spinal cord where primary afferent fibers,
from sciatic nerves innervating hind limb including the hind
paw, form synapses with dorsal sensory neurons [34,35]. At
36–40 minutes after formalin injection, we confirmed the
change of c-Fos expression in the ipsilateral DH of the L4-L5
spinal cord (Figure 2A). c-Fos expression was upregulated in
the spinal DH of formalin-induced rats compare to normal,
saline- pretreated and saline-treated rats. However, the ele-
vated level of c-Fos expression was decreased by EP-
administration (100 mg/kg, i.p.) (Figure 2A). In addition, we
evaluated the anatomical distribution of c-Fos expression in
spinal DH (Figures 2B-2E). The c-Fos-IR in the L4-L5 spinal
DH was very scarce in normal rats (I-IV, 28.9±3.4; I-II,
11.3±1.9; III-IV, 17.5±1.8). The number of c-Fos-IR cells in
the superficial and deep laminae was extensively increased
following intraplantar injection of formalin (I-IV,
74.1± 3.4; I-II, 48.6 ± 2.3; III-IV, 25.6± 2.0), but the
formalin-induced c-Fos-IR enhancement was significantly
decreased by EP-administration (100 mg/kg, i.p.) 1 hour prior
to formalin injection (I-IV, 45.9±7.9; I-II,31.0±6.4; III-IV,
Figure 1 Change of nociceptive response and hind paw edema following ethyl pyruvate (EP) administration. (A) Effects of the systemic
administration of ethyl pyruvate (EP) (10, 50, and 100 mg/kg) on paw licking and lifting responses following intraplantar injection of formalin (5%, 50 μl)
into the hind paw. The rats receiving saline vehicle showed typical biphasic nociceptive behavior. While phase I nociceptive response was similar between
the saline- and EP-injected rats, phase II nociceptive behavior was significantly reduced by EP administration 1 hour prior to formalin injection. All results
are presented as mean±SEM. Student's t test was performed at each time point after formalin injection. Values are expressed as mean±SEM. *P<0.01;
**P<0.05 vs. control rats (saline-pretreated and formalin-treated). Saline (n=15), EP 10 mg/kg (n=14), 50 mg/kg (n=10), and 100 mg/kg (n=13). (B) Total
time of nociceptive behaviors during phase II. Total times of licking and lifting were attenuated by EP in a dose-related fashion following intraplantar
injection of formalin. Values are expressed as mean±SEM. *P<0.01 vs. control rats (saline-pretreated and formalin-treated). (C) Effects of EP on the
magnitude of hind paw edema following formalin injection. An index of paw edema was calculated as the mean difference of paw thickness (thickness of
the ipsilateral paw after injection/thickness of the ipsilateral paw before injection×100). EP significantly reduced formalin-induced edema compared to the
control. Values are expressed as mean±SEM. *P<0.01 vs. control rats (saline-pretreated and formalin-treated).
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the contralateral DH was similar to that in the spinal DH
of normal rats (data not shown). EP (100 mg/kg, i.p.),
itself did not have any effect on c-Fos expression in the
spinal cord. Taken together, the above results suggest
that EP has an inhibitory action in spinal sensitization
in formalin-induced acute inflammatory nociception
(Figures 2B-2E).EP attenuates formalin-induced neuronal p-ERK
expression
ERK 1/2 are expressed in the spinal cord and are acti-
vated in rat spinal DH neurons after inflammation
[20,36]. Inhibitors of ERK signaling reduce nociceptive
response in the phase II of the formalin test, suggesting
a selective role for ERK 1/2 in nociceptive sensitization
[20]. In addition, ERK phosphorylation is inhibited in the
Figure 2 Representative photomicrographs and graph showing immunoreactivity of c-Fos in the spinal DH (L4-5) following formalin
injection. (A) Western blots from spinal DH. N, normal. FA, saline-pretreated and formalin-treated rats, FA + EP, EP-pretreated and formalin-treated
rats. E, EP alone. (B-D) Photomicrographs showing c-Fos expression in the spinal DH from normal rats (B), saline-pretreated and formalin-treated
rats (C), EP-pretreated and formalin-treated rats (D). The elevated number of c-Fos-immunorective (IR) cells produced by formalin was clearly
decreased in both the superficial lamina (I-II) and deep lamina (III-IV) by EP-pretreatment. Insets are high magnification of the open rectangles.
Scale bar = 100 μm. (E) The number of c-Fos-IR cells in spinal DH following EP pre-injection. The mean number of c-Fos-IR cells was calculated by
averaging the total numbers per each region. Values are expressed as mean± SEM. +P < 0.01 vs. normal rats (saline-pretreated and saline-treated);
*P < 0.01 vs. control rats (saline-pretreated and formalin-treated).
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Therefore, we investigated whether EP could produce its
effects through the ERK 1/2 signaling pathway in the
formalin-induced nociception. As illustrated in Figure 3A,
at 36- 40 minutes after formalin treatment, we observed
a clear phosphorylation of ERK 1/2 in the L4-L5 spinal
DH. However, the elevated level of the phosphorylation
of ERK 1/2 was decreased by EP administration (100
mg/kg, i.p.) (Figure 3A). Subsequently, we examined the
spinal distribution of the phosphorylation of ERK 1/2
(Figures 3B-3E). Immunohistochemical evaluation con-
firmed that p-ERK-IR cells in the L4-L5 spinal DH were
very scarce in saline-administrated normal rats (I-IV,
12.6±1.2; I-II, 12.3± 0.6; III-IV, 6.3±0.3) (Figures 3B and
3E). The number of p-ERK-IR cells in lamina I-II of the
spinal DH was significantly increased by formalin treatment
(I-IV, 62.9±7.2; I-II, 59.9± 2.7; III-IV, 19.2± 1.0), but these
formalin-stimulated p-ERK enhancements were decreasedby EP-administration (I-IV, 30.4± 3.8; I-II, 33.3± 2.2; III-IV,
13.7±0.6) (Figures 3C-3E).
To investigate the nature of the p-ERK-IR cells, we
examined whether the ERK 1/2 are activated in neurons,
microglia, or astrocytes using a multiple immunofluores-
cence method. Interestingly, the p-ERK immunofluores-
cence in the spinal DH was found exclusively in
neurons (83.1%; 103 p-ERK-IR and NeuN-IR neurons of
124 p-ERK-IR neurons) (Figures 4A-4C), but not clear in
microglia or astrocytess (Figures 4D-4I). Also microglia and
astrocytes were not sufficiently activated 36–40 minutes
after formalin treatment (Figures 4E, 4H, 4J and 4K). These
results suggest that EP attenuates the formalin-induced
acute inflammatory nociception through the inhibition of
neuronal ERK activation, but not glial ERK activation.
Because p38 and c-Jun, N-terminal kinase (JNK)
MAPKs are activated in microglia and astrocytess, respect-
ively, after a variety of nerve damage, and both MAPKs
Figure 3 Phosphorylation of ERK1/2 in the DH of spinal cord (L4-L5) after saline or EP pretreatment. (A) Western blots from spinal DH. N,
normal. FA, saline-pretreated and formalin- treated rats, FA+ EP, EP-pretreated and formalin-treated rats. E, EP alone. (B-D) Photomicrographs showing
c-Fos expression in the spinal DH from normal rats (B), saline-pretreated and formalin-treated rats (C), EP-pretreated and formalin-treated rats (D). The
number enhancement of p-ERK-IR cells produced by formalin was clearly decreased in both the superficial lamina (I-II) and deep lamina (III-IV) by
EP-pretreatment. Insets are high magnification of the open rectangles. Scale bar = 100 μm. (E) The number of p-ERK-IR cells in spinal DH following EP
preinjection. The enhancement in the number of p-ERK positive cells produced by formalin was significantly decreased in spinal DH by EP pre-
administration. The mean number of p-ERK positive cells was calculated by averaging the total numbers per each region. Values are expressed as
mean± SEM. +P < 0.01 vs. normal rats (saline-pretreated and saline-treated); *P < 0.01 vs. control rats (saline-pretreated and formalin-treated).
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various forms of nociception [21,27,37], we also investi-
gated whether both MAPKs are regulated by formalin or
EP. Unlike the very low level of basal p-ERK, moderate
basal p-p38 and p-JNK were evident in the spinal DH.
Nonetheless, p- p38 and p-JNK were not increased or
inhibited by hind paw formalin injection or EP administra-
tion into the peritoneal cavity (Additional file1: Figure S1).
Microglia are not morphologically activated or inhibited
by formalin or EP
Spinal microglia are activated in inflammatory and neuro-
pathic pain [38], and EP attenuates inflammation through
the inhibition of microglial activation in various neuro-
logical disease models [18,28]. Therefore, we examined
whether spinal microglia are activated 36–40 minutes after
formalin injection (i.e., when formalin produces the max-
imum nociceptive effects on formalin-induced pain) and ifso, whether the activated spinal microglia is inhibited by
EP administration. Activated microglia usually display
CD11/b- or Iba-1 (a marker for microglia/macrophage
lineage cells)-IR with enlarged cell bodies and much
shorter and thicker processes [28,39]. However, when we
analyzed CD11/b-IR cells 36–40 minutes following forma-
lin injection, microglial activation by formalin and EP-
induced inhibition were not clearly evident in ipsilateral
DH compared to normal spinal DH (Figures 4E and 4J).
The results were consistent with previous studies
[28,30,40], which reported that at least 1 day was required
for the expression of OX-42-IR.
To examine whether the EP could inhibit microglial
activation in our formalin-induced inflammatory noci-
ception model, we administrated EP (100 mg/kg, i.p.) to
formalin-injected rats once daily for 3 days. When we
analyzed Iba-1-IR in spinal DH 3 days following forma-
lin injection, microglia was clearly activated by formalin
Figure 4 Representative photomicrographs showing p-ERK-IR in the spinal DH (L4-L5) of formalin-treated rats. (A-I) p-ERK-IR in the
spinal DH of the saline-pretreated and formalin treated rats. The p-ERK-IR was found exclusively in spinal DH neurons (A-C), but not in microglia
(D-F) or astrocytes (G-I). (J,K) Microglia (J) and astrocytes (K) in normal rat (salinepretreated and saline-treated). Scale bar = 50 μm.
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rats. However, this microglial activation was remarkably
inhibited by EP administration (Figures 5A-5D). These
results confirmed that spinal microglia was not affected
in cell morphology by either formalin or EP during
phase II of the formalin-induced pain model, and that
spinal microglia do not contribute to acute inflamma-
tory pain.Figure 5 Photomicrographs showing changes in CD11/b-IR in the spi
EP on microglial activation were clear at 3 days following formalin injection
Contralateral spinal DH of saline-pretreated and formalin-treated rats. (B) Ip
Ipsilateral spinal DH of EP-pretreated and formalin-treated rats. Scale bar = 5
intensity per 0.5 mm2 area within medial portion of the L4-L5 spinal DH at
increased by formalin injection, however this increased intensity significant
normal rats (saline-pretreated and saline-treated) or control rats (saline-pretI.T. Administration of PD-98059 reduces formalin-induced
inflammatory nociception
After intraplantar injection of formalin, nociceptive behav-
ior increased and p-ERK expression was up-regulated,
mainly in DH neurons of L4-L5 spinal segments, but not
in microglia and astrocytes. The elevated nociceptive re-
sponse and p-ERK expression were remarkably reduced by
i.p. administration of EP (Figures 1 and 3). These resultsnal DH (L4-L5) 3 days after formalin injection. Inhibitory effects of
. Insets are high magnification of the open rectangles. (A)
silateral spinal DH of saline-pretreated and formalin-treated rats. (C)
0 μm. (D) The Iba-1-IR intensity was measured as the average pixel
3 days after formalin injection. The Iba-1-IR intensity was significantly
ly decreased by EP. Values are expressed as mean± SEM. *P < 0.01 vs.
reated and formalin-treated).
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may contribute to formalin-induced nociception. To ad-
dress this issue, we directly introduced the MEK inhibitor,
PD-98059, to subarachnoid space of normal rats. In the
vehicle-treated rats, the duration of nociceptive re-
sponse by formalin stimulation peaked at 36–40 min-
utes (34.4 ± 5.3 seconds/minute), and then gradually
declined. Total duration of nociceptive behavior during
phase II was 213.0 ± 32.7 seconds (Figures 1A and 1B)
similar to the result of Figure 1B. However, these noci-
ceptive responses were almost completely blocked by
the i.t. administration of PD-98059 in a dose-dependent
manner in peak time (5 μg, 19.7 ± 5.8 seconds/minute;
10.0 μg, 11.3 ± 5.0 seconds/minute), and total durationFigure 6 Intrathecal administration of PD-98059 inhibits formalin (5%
formalin-induced nociceptive behavior. The nociceptive behavior by forma
PD-98059 in a dose dependent manner. Values are expressed as mean± SE
formalin-treated). (B) Total times of nociceptive behavior were remarkably
administration of PD-98059 in a dose-related fashion following intraplantar
control rats (vehicle-pretreated and formalin-treated).of nociceptive behavior (5 μg, 96.0± 26.7 seconds/minute;
10.0 μg, 64.0± 19.1 seconds/minute) during phase II was
also decreased (Figures 6A and B). These results indicate
that i.t. introduction of PD-98059 inhibits formalin-
induced inflammatory pain.
Discussion
In the current study, we investigated the possibility that EP
may be potential analgesic for formalin-induced inflamma-
tory nociception. When EP was administrated intraperi-
toneally 1 hour before formalin injection into the
plantar surface of the hind paw, it attenuated nocicep-
tive behavior, the size of hind paw edema (Figure 1), and
the activation of c-Fos and ERK in the neurons of L4-L5, 50 μl, i.p.)-induced inflammatory nociception. (A) Time course of
lin injection was significantly inhibited by intrathecal administration of
M. *P < 0.01, and **P < 0.01 vs. control rats (vehicle-pretreated and
blocked during phase II, but not during phase I by intrathecal
injection of formalin. Values are expressed mean± SEM. *P < 0.01 vs.
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of its central and peripheral pharmacological actions. In
addition, the i.t. introduction of the MEK inhibitor,
PD-98059, reduced formalin-induced inflammatory noci-
ception (Figure 5). These data indicate that neuronal ERK
phosphorylation is involved in the acute inflammatory
nociceptive mechanism, and the EP can attenuate acute
inflammatory nociception by inhibiting neuronal ERK ac-
tivation in spinal DH.
Subcutaneous hind paw injection of formalin elicits two-
phase nociceptive responses. While phase I is considered to
reflect acute nociceptive pain by a direct stimulation of the
nerve by the formalin, phase II is attributed to the combin-
ation of ongoing inflammatory-related afferent input from
peripheral tissue and functional changes in the spinal DH
(central sensitization) [29,41]. In the current study, adminis-
tration of EP clearly reduced the size of hind paw edema by
formalin stimulation and nociceptive behavior during phase
II, but not during phase I (Figure 1A). And it has been
demonstrated that most peripheral inflammation is often ac-
companied by a variety of pain [42], and that EP seems to
exert pharmacological effects, such as suppression of inflam-
mation (i.e., severe sepsis, acute pancreatitis) [2]. It also has
been reported that EP has an anti-inflammatory effect in the
nervous system by inhibiting microglial activation in models
of stroke and neural damage [6,7,17,18,43]. Based on these
collective findings, we suggest that EP could produce anti-
nociceptive effect by regulating peripheral and/or central
mechanisms underlying formalin-induced inflammatory
nociception.
Intraplantar injection of formalin produces a massive in-
flammatory response at the injection site [29], thereby caus-
ing paw edema [30]. To verify the peripheral effect of EP, we
examined the changes of hind paw edema 1 hour following
formalin injection. When rats were given EP injection 1 hour
before formalin injection, the thickness of hind paw edema
was significantly decreased (12.5~25.7%) compared to that
of animals treated with formalin alone (Figure 5). Reduction
of the formalin-induced paw edema by EP (Figure 1C) sug-
gests its clear anti- edematous effects in the inflammatory
site. Several mechanisms could explain the anti-edematous
effects of EP for formalin-induced inflammation. First, EP
may inhibit the activation and recruitment of peripheral im-
mune cells to formalin-induced inflammatory site. Jang et al.
[44] recently demonstrated that EP has the ability to inhibit
neutrophil activation, inflammatory cytokine (TNF-α, IL-1β)
release, and nuclear factor κB (NF-kB) translocation in ische-
mia/reperfusion-induced heart injury. Second, EP may in-
hibit peripheral inflammation such as adenosine. It has been
demonstrated that the i.t. administration of the adenosine re-
ceptor agonist, cyclohexyladenosine (5 μg/kg), suppresses
peripheral inflammation by decreasing neutrophil infiltration
into skin lesions [45]. Third, like botulinum toxin A, EP may
reduce neurogenic inflammation in the inflamed skin byreducing the releasing of neurotransmitters such SP, CGRP
and glutamate from peripheral sensory nerve terminals by
formalin injection. Released neurotransmitters contribute to
the formalin-induced edema [46]. Peptide-mediated trans-
dermal delivery of botulinum neurotoxin type. A reduces
neurogenic inflammation in the skin [47]. The detailed
cellular and molecular mechanisms underlying the anti-
edematous effects of EP in the periphery remain to be elu-
cidated. The detailed cellular and molecular mechanisms
underlying the anti-edematous effects of EP in the periph-
ery remain to be elucidated.
To verify the possible central mechanism of EP, we exam-
ined the changes in c-Fos expression in the spinal DH dur-
ing phase II (the peak time point of nociception; 36–40
minutes after formalin injection) of formalin-induced noci-
ception. In agreement with our previous report [28], the in-
crease in formalin-induced c-Fos expression was mainly
observed in the L4-L5 superficial and deep laminae where
the primary nociceptive afferents from spinal nerve termin-
ate (Figure 2). However, the upregulation of c-Fos expres-
sion by formalin stimulation was clearly inhibited by EP
(Figure 2). Because c-Fos is expressed in the spinal cord
subjected to many kinds of peripheral noxious stimulation
[31-33], the reduction of c-Fos expression in the spinal DH
clearly indicates an anti-nociceptive role of EP.
Accumulating evidence shows that MAPKs (ERK, p38,
and JNK) pathways contribute to pain sensitization after
tissue/nerve injury via distinct molecular/cellular mechan-
isms [24-27]. In particular, ERK mediates intracellular signal
transduction in response to a variety of stimuli. The phos-
phorylation of ERK in the nociceptive neurons of spinal DH
occurs in response to axotomy, electrical stimulation to the
peripheral nerve, noxious stimulation of the peripheral tis-
sue, and peripheral inflammation [20,27]. The phosphoryl-
ation of ERK plays a critical role in central sensitization by
regulating the activity of glutamate receptors and potassium
channels, and inducing gene transcription, and thereby con-
tributes to persistent inflammatory and neuropathic pain
[27]. These reports suggest that the materials regulating the
phosphorylation of ERK could control nociceptive mechan-
ism. Presently, ERK was phosphorylated in mainly neurons
of L4-L5 spinal DH by formalin-injection; 83.1% of p-ERK
IR cells were NeuN-IR cells (Figure 4). However, the elevated
p-ERK expression by formalin injection was clearly attenu-
ated by EP administration (Figure 3). In accordance with
these results, it was recently reported that EP can suppress
the phosphorylation of ERK in LPS-stimulated BV2 cells
[15]. These results indicate that EP could inhibit inflamma-
tory nociception by regulating the phosphorylation of ERK
in neurons of spinal DH after formalin injection.
I.t. injection of the MEK inhibitor, PD-98059, blocks
the central sensitization-mediated phase II of the painful
response to formalin injection [27,48]. MEK dominant
negative mutant mice in which MEK function is
Lee et al. Molecular Pain 2012, 8:40 Page 9 of 13
http://www.molecularpain.com/content/8/1/40suppressed exclusively in neurons show decreased phase
II responses in the formalin-induced nociception [49].
The MEK inhibitor, U0126, also blocks secondary mech-
anical hypersensitivity from central sensitization following
intraplantar injection of capsaicin [50]. In addition, i.t.
injection of MEK inhibitors inhibits inflammatory thermal/
mechanical hypersensitivity following intraplantar injection
of bee venom [51] and CFA [19,52], and in a model of
monoarthritis and inflammatory visceral pain [26,53]. I.t.
MEK inhibitors can also suppress neuropathic pain by
streptozotocin-induced diabetes and spinal cord injury
[54,55]. Presently, we verified that PD-98059 completely
blocked formalin-induced nociception during phase
II (Figure 6). These results suggest that the phosphoryl-
ation of spinal ERK could play a critical role in
development and maintenance of formalin-induced in-
flammatory nociception.
Because EP has an anti-inflammatory effect in the ner-
vous system by inhibiting the microglial activation in a
model of stroke and excitotoxic neuronal damage, and
in a LPS-stimulated in vitro model [6,7,17,18,43], we can
speculate that central pharmacological roles of EP could
target the microglial activation of spinal DH following
formalin injection. However, morphological changes of
CD11/b-IR microglia was not clearly observed at the
peak time of nociception, 36–40 minutes after formalin
injection, and the CD11/b-IR microglia was also not
affected by EP at the same time, indicating that EP pro-
duced its maximal effect. Microglia was sufficiently acti-
vated 3 days after formalin injection, and the activated
microglia was completely inhibited by EP (Figure 5).
These findings were consistent with previous reports
that CD11/b- or OX-42-IR microglia are not distinctly
activated as early as 1 hour following formalin injection,
but only increase after 1 day and peak 7 days following
formalin injection [28,30,40,56]. Thus, the collective
findings suggest that microglial activation might not dir-
ectly contribute to the anti-nociceptive effects of EP on
the early stage of formalin-induced nociception.
After nerve damage, the three MAPKs are differen-
tially activated in spinal neurons and glial cells by vari-
ous postsynaptic receptors and multiple protein kinases,
and the activated glial cells induces the synthesis of pro-
nociceptive and proinflammatory mediators that act to
develop and maintain pain [27]. ERK integrates multiple
signaling pathways and regulates the Kv4.2 potassium
channel in the spinal cord, and contributes to the induc-
tion and maintenance of central sensitization via post-
translational and transcriptional regulation, respectively
[27]. ERK is activated in neurons from 10 minutes to 6
hours, in microglia on day 2, in both microglia and
astrocytes on day 10, and in astrocytes on day 21 after
spinal nerve ligation [24]. In agreement with these
reports, we confirmed that ERK was phosphorylatedmainly in the spinal neurons, but not microglia and
astrocytess at 36–40 minutes after formalin injection,
and that the elevated ERK phosphorylation was inhibited
by EP. These results suggest that the inhibition of neur-
onal phosphorylation of ERK in spinal DH might be
associated with anti-nociceptive effects produced by EP.
Compared to mechanisms of ERK pathway in neuro-
pathic pain, neuronal and glial mechanisms of ERK for
inflammatory nociception control remain to be eluci-
dated. p38 and JNK are phosphorylated in primarily
spinal microglia and astrocytes, respectively, after per-
ipheral inflammation and peripheral nerve injury [57-59].
The activation of the p38 and JNK in microglia and astro-
cytes is critical for the maintenance of inflammatory/
neuropathic pain. Therefore, we investigated whether the
phosphorylation of p38 and JNK were increased in spinal
DH at peak time point of nociceptive behavior after for-
malin injection. Expression of p-p38 and p-JNK was not
increased or decreased in spinal DH by formalin injection
or EP administration (Additional file 1: Figure S1). These
findings are supported by that p-p38 begins to increase at
12 hours, reaches a peak at 3 days after a spinal nerve
ligation, and is maintained at elevated levels even after 3
weeks [24,57], and that p-JNK is persistently increased in
spinal astrocytes at 1, 3, 10, and 21 days after spinal nerve
ligation [59] and partial sciatic nerve injury [21]. There-
fore, our findings suggest that p38 and JNK might not dir-
ectly contribute to the development and maintenance of
hypersensitivity in the formalin-induced nociception.
Interestingly, recent publications reported contradictory
results in the expression time of p-p38; p38 was rapidly
activated in the spinal microglia minutes following intra-
thecal administration of substance P or intradermal injec-
tion of formalin and the activation persisted for 1 hour
[38,60]. In addition, induction of a secondary increase of
p-p38 expression in spinal microglia occurred and was
maximal 3 to 7 days after injection [60]. The exact role of
p-p38 and microglia in inflammatory pain are still unclear.
Future studies should investigate the clear function of ac-
tivation of MAPKs signaling pathway in various pains.
Conclusions
While increased spinal ERK phosphorylation is import-
ant for pain behaviors based on the MEK inhibitor stud-
ies, the direct link between EP’s inhibitory effects in
inflammatory nociceptive responses and its modulating
effects on p-ERK expression has not been established. In
this study, EP attenuated the inflammatory nociceptive
response, the size of hind paw edema and the activation
of spinal c-Fos and ERK 1/2 in the formalin-induced in-
flammatory pain. And, the i.t. introduction of MEK in-
hibitor PD-98059 reduced the nociceptive behavior by
formalin. These results strongly suggest that EP has an
anti-nociceptive effect on formalin-induced inflammatory
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All experiments were approved by the Institutional Ani-
mal Care and Use Committee (IACUC) in College of
Oriental Medicine, Kyung Hee University. And animal
treatments were performed according to the ethical
guidelines of the International Association for the Study
of Pain for the investigation of experimental pain in con-
scious animals [61]. The male Sprague–Dawley (SD) rats
(weight, 250–280 g) were kept at a constant temperature
of 23 ± 3°C with a 12-h light–dark cycle (light on 08:00
to 20:00), and fed food and water ad libitum. The ani-
mals were allowed to habituate to the housing facilities
for 1 week before the experiments.
Formalin-induced behavioral test
The formalin-induced nociceptive response was tested
as described previously [28]. Briefly male SD rats were
randomly assigned to two groups; saline-treated control
group (n = 15), and EP-treated experimental group
(n = 37). Three EP-treated group received EP (Sigma-
Aldrich, USA) at doses of 10 mg/kg (n = 14), 50 mg/kg
(n = 10) or 100 mg/kg (n = 13) intraperitoneally 1 hour
before formalin injection, respectively (Figure 7A). Con-
trol rats received an equal volume of saline vehicle. The
dosage of EP was determined based on doses used in pre-
vious reports of the therapeutic effects of EP [9,12,62].
The time point of formalin injection was determined
based on a previous report of the optimal delivery of EP
in rats [9,12,62]. Following intraplantar injection of forma-
lin (5%, 50 μl) into the right hind paw, rats were placed in a
clear plastic cage (20×26×12 cm) without bedding, and
the total time of pain responses, licking/rubbing on the
injected area or lifting the paw, was counted in 5 minutes
interval for 60 minutes. The behavioral tests wereFigure 7 Schematic drawing representing the experimental protocol
PD-98059 treatments. IHC, immunohistochemistry; WB, Western blots; i.plperformed blinded under the constant condition
(temperature, 23±3°C; humidity, 55±5%) between 9:00 am
and 12:00 am in a quiet room.
Measurement of paw edema
For the measurement of paw edema, we adopted the
method described previously [28,30,63]. The foot thick-
ness in the dorsal-plantar axis was measured with a fine
caliper (Mitutoyo, Japan) before and 1 hour after forma-
lin injection (Figure 7A). And the index of paw edema
was calculated as the mean difference of paw thickness
(thickness of the ipsilateral paw after formalin injection/
thickness of the ipsilateral paw before formalin injec-
tion × 100). Evaluation of paw edema was also performed
by an experimenter unaware of the experimental
condition.
Immunocytochemical evaluation
The anti-nociceptive effect of EP (100 mg/kg, i.p.)
peaked around 36–40 minutes after intraplantar injec-
tion of formalin. So, at that time following formalin in-
jection, rats for immunohistochemical evaluation (n = 8
per group) were anesthetized i.p. with 40 mg/kg sodium
pentobarbital, and perfused with fresh 4% paraformalde-
hyde in 0.1 M phosphate buffer (pH 7.4) (Figure 7A).
The L4-L5 spinal segments were removed and postfixed
at 4°C overnight and then cryoprotected in 0.1M PBS
(pH 7.4) containing 30% sucrose for 48 hours at 4°C.
Immunostaining was carried out according to previously
established procedures [28,39,64]. Briefly, eight trans-
verse sections (30 μm thickness) in 500 μm interval
selected from each animal were incubated for 30 min-
utes with 3% H2O2 in 0.1M PBS (pH 7.4) to remove en-
dogenous peroxidase activity, and then blocked with
solution containing 5% normal goat/or horse serum, 2%
BSA, 2% FBS and 0.1% triton X-100 for 2 hours at room
temperature (RT). The sections were incubated overnight
at 4°C with either rabbit anti-c-Fos (1:10,000; Oncogene,used for inflammatory pain with formalin, ethyl pyruvate (EP) and
., intraplanter; i.p., intraperitoneal.
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naling, U.S.A.), and then washed in PBS. Sections were
then incubated with biotinylated secondary antibodies
(Vector Laboratories, Burlingame, CA) at a dilution of
1:200 for 1 hour at RT, followed by incubation with avidin
and biotinylated HRP complex (Vector Laboratories) at
1:200 for 1 hour at RT. All sections were visualized with
3,3′-diaminobenzidine (D-5637; Sigma, U.S.A.). The
immunostained sections were mounted onto gelatinized
glass slides, dehydrated through a series of ethanol,
cleared, and cover-slipped with permount. Images of
stained sections were visualized and captured using a
digital microscope system (DP70, Olympus, Japan) under
light microscope. Superficial laminae (I-II) and deep lam-
inae (III-IV) were outlined, and the c-Fos- or p-ERK-
immunoreactive (IR) cells were counted. Evaluation of the
immunostained sections was performed by an experi-
menter unaware of the experimental condition.
Immunofluorescence evaluation
For double immunofluorescent staining, sections were
incubated overnight at 4°C with a mixture of rabbit anti-
p-ERK antibody and mouse anti-NeuN (1:500; Chemi-
con, U.S.A), or rat anti-CD11/b, or mouse anti-GFAP
(1:1,000; Chemicon, U.S.A) antibody. The sections were
then incubated for 1 hour at RT with mixture of Cy3-
and FITC-conjugated rabbit/rat/mouse IgG antibody
(1:200; Jackson ImmunoResearch, U.S.A.), and then
examined with confocal imaging system (LSM 5 PAS-
CAL; Carl Zeiss, Germany). Immunofluorescence images
for Iba-1 antibody were analyzed as described previously
[65]. In brief, the images were captured using confocal
microscopy and changes in immunofluorescence inten-
sity of Iba-1 expression in the spinal DH after formalin
injection were quantified by measuring the average pixel
intensity per 0.5 mm2 area within the medial portion of
the superficial and deep laminae of the spinal DH in four
sections per rat at the level of L4-5 spinal segments 3
days after formalin injection.
Western blot analysis
To investigate the level of protein expression, EP (100
mg/kg) was injected i.p. 1 hour before the intraplantar
injection of formalin. And at 36–40 minutes after forma-
lin injection, L4-L5 spinal segments were removed with
lysis buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1%
Triton X-100, 10% glycerol, and protease inhibitor mix-
ture) (Figure 7A). A total of 50 μg of tissue lysate from
each sample was resolved by electrophoresis on a 10%
SDS-PAGE. The proteins were then transferred to PVDF
membranes and blocked with 5% nonfat dry milk in
Tween 20-containing Tris-buffered saline (TBST, 20
mM Tris, pH 7.4, 0.1% Tween 20, and 150 mM NaCl).
The membranes were probed overnight with primaryantibody (p-ERK, p-p38, or p-JNK at 1:2,000; Cell Sig-
naling, U.S.A.) at 4°C, which was followed by incubation
with HRP-conjugated secondary antibody at RT for 1 hour
prior to ECL treatment and exposure to X-ray film. For
normalization of antibody signal, the membranes were
stripped and reprobed with antibodies for ERK 1/2 or actin.
Intrathecal (I.T.) administration of PD-98059
The i.t. injections were performed under light isofluran
anesthesia (1-2%). The dorsal fur of each rat (saline+ formalin,
n=10; 5 μg of PD-98059+ formalin, n=9; 10 μg of PD-
98059+ formalin, n=9) was shaved, the spinal column was
arched, and a 30-gauge needle was directly inserted into the
subarachnoid space, between the L5 and L6 vertebrae [66].
Correct i.t. positioning of the needle tip was confirmed by
manifestation of a characteristic tail flick response. The 5
and 10 μg of the ERK upstream kinase (MEK) inhibi-
tor PD-98059 (2-amino-3′-methoxyflavone; Calbiochem,
USA), or vehicle (saline alone or 10% dimethylsulfoxide)
were slowly injected into the rat with a 50 μl Hamilton
micro syringe in a total volume of 5 μl. The entire injection
procedure, from the induction of anesthesia until recovery of
consciousness, took 4–5 minutes. Preliminary injections were
performed with a similar volume of 10% India ink solution
and the reliability and accuracy of this method was con-
firmed by subsequent dissection of the lumbar spinal cord.
The success rate for the prior injections with this technique
was over 97.5%. The same investigator performed all injec-
tions. The intraplantar injection of formalin and behav-
ioral test were performed 20 minutes after i.t. injection
of PD-98059 as described above (Figure 7B).
Statistical analysis
The statistical significance of differences between the
values was determined using the ANOVA with a Fisher's
post hoc test. All data are presented as the mean ± S.E.M.
and a statistical difference was accepted at the 5% level
unless indicated otherwise.Additional file
Additional file 1: Figure S1. Phosphorylation of p-p38 and p-JNK in
the DH of spinal cord (L4-L5) after saline or EP pretreatment. N, normal
rats (saline pretreated + saline treated); FA, saline pretreated + formalin
treated; E + F, EP (100 mg/kg, i.p.) pretreated + formalin treated; E, EP
(100 mg/kg, i.p.) treated.
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